• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cadre Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    1/27/25 4:16:20 PM ET
    $CDRE
    Industrial Specialties
    Health Care
    Get the next $CDRE alert in real time by email
    false 0001860543 0001860543 2025-01-24 2025-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Form 8-K

    Current Report 

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 24, 2025

     

    CADRE HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-40698 38-3873146
    (State or other jurisdiction (Commission File Number) (IRS Employer
    of incorporation)   Identification Number)

     

    13386 International Pkwy  
    Jacksonville, Florida 32218
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (904) 741-5400

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol Name of each exchange on which
    registered
    Common Stock, par value $.0001 CDRE New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

      x Emerging growth company

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Employment Agreement with Brad Williams

     

    On January 24, 2025, Cadre Holdings, Inc. (the “Company”) and Mr. Brad Williams entered into an Employment Agreement (the “Williams Employment Agreement”), which provides for Mr. Williams’ continued employment as President of the Company, for a term commencing effective as of January 24, 2025 (the “Commencement Date”) and terminating on the third anniversary of the Commencement Date, subject to earlier termination as provided therein. Mr. Williams is entitled to an annual base salary of $625,000, as more particularly provided in the Williams Employment Agreement.

     

    In addition to any other bonuses that the Company’s Board of Directors (the “Board”) or the Compensation Committee of the Board may award to Mr. Williams in their sole discretion, Mr. Williams is entitled to receive annual performance bonuses, which may be based upon a variety of qualitative and quantitative factors, of up to 150% of Mr. Williams’ annual base salary. Mr. Williams will also be entitled, at the sole and absolute discretion of the Board or the Compensation Committee, to participate in incentive plans of the Company, including but not limited to the Company’s 2021 Incentive Plan or such other stock incentive plan as the Company may have in effect from time to time. Such participation and awards shall be based upon, among other things, Mr. Williams’ performance and the Company’s performance, all as determined by the Compensation Committee of the Board, of up to 150% of the Base Compensation, which will be payable 50% in the form of stock options and 50% in the form of a restricted stock award.

     

    The Williams Employment Agreement also contains confidentiality obligations as well as a non- competition covenant and non-interference (relating to the Company’s customers), non-solicitation (relating to the Company’s employees) and non-disparagement provisions effective during the term of his employment and for a period of two years after the termination of his employment with the Company.

     

    In the event that Mr. Williams’ employment is terminated as a result of his death or disability, Mr. Williams or his estate will, subject to the provisions of the Williams Employment Agreement, be generally entitled to receive his accrued base salary through the date of such termination and earned but unpaid annual incentive bonus prorated for the portion of the year in which such termination occurred and all granted but unvested stock options and all unvested restricted stock (and only if the price target as set forth therein has been achieved, including the restricted stock grant awarded pursuant to Section  3(e) of the Employment Agreement dated as of July 9, 2021, by and between the Company and Mr. Williams (the “2021 Williams Restricted Stock Award”) shall immediately vest. In the event that Mr. Williams’ employment is terminated by the Company for “cause” (as defined in the Williams Employment Agreement), Mr. Williams will, subject to the provisions of the Williams Employment Agreement, be entitled to receive his accrued base salary through the date of such termination. In addition, all stock options, whether vested or unvested, and granted but unvested restricted stock will be null and void except that, in the event that Mr. Williams is terminated as a result of his failure to perform any reasonable directive of the Board, he will be entitled to retain any vested stock options, but subject to the terms of the respective plan and award agreement under which they were awarded.

     

    In the event that Mr. Williams’ employment is terminated by the Company without “cause” (as defined in the Williams Employment Agreement), Mr. Williams will, subject to the provisions of the Williams Employment Agreement, be entitled to receive an amount equal to one year of his base salary and reimbursement of any COBRA premium payments made by Mr. Williams during such one-year period, in each case payable in accordance with the Company’s normal payroll practices, provided that Mr. Williams executes a separation agreement and general release agreement that is satisfactory to the Company. In addition, all granted but unvested stock options and all unvested restricted stock (but not including the 2021 Williams Restricted Stock Award) will immediately vest.

     

    In the event that Mr. Williams’ employment is terminated by Mr. Williams other than as a result of a “change in control” (as defined in the Williams Employment Agreement), Mr. Williams will, subject to the provisions of the Williams Employment Agreement, generally be entitled to receive his accrued base salary and benefits through the date of such termination. In addition, all granted but unvested stock options and all unvested restricted stock will be null and void.

     

     

     

     

    In the event that Mr. Williams’ employment is terminated by either party within 30 days of a “change in control”, Mr. Williams will, subject to the provisions of the Williams Employment Agreement, generally be entitled to receive an amount equal to one year of his base salary payable in one lump sum within five business days after such termination and reimbursement of any COBRA premium payments made by Mr. Williams during such one-year period; provided that Mr. Williams executes a separation agreement and general release agreement that is satisfactory to the Company, and provided further that, in the event the Company or the acquiror requests Mr. Williams to provide consulting services described in the Williams Employment Agreement, then the lump sum payment of an amount equal to one year of his base salary shall be payable upon the expiration of such consulting period, and during such consulting period, Mr. Williams will be entitled to a consulting fee equal to what he would have otherwise been entitled to be paid under the Williams Employment Agreement during such period. In addition, all granted but unvested stock options and all unvested restricted stock (and only if the price target as set forth therein has been achieved, including the 2021 Williams Restricted Stock Award) shall immediately vest.

     

    In the event that Mr. Williams fails to comply with any of his obligations under the Williams Employment Agreement, including, without limitation, the non-competition covenant and the non-interference, non-solicitation and non-disparagement provisions, Mr. Williams will be required to repay the one year of base salary paid to him pursuant to the Company termination without cause or change in control provisions of the Williams Employment Agreement as of the date of such failure to comply and he will have no further rights in or to such payments payable to him pursuant to the Williams Employment Agreement. All payments and benefits provided under the Williams Employment Agreement shall be subject to Company’s compensation recovery policy and/or as required under applicable law, rule or regulation.

     

    The Williams Employment Agreement contains provisions designed to reduce (but not below zero) any payments otherwise required to be paid to Mr. Williams if the same would result in the imposition of an excise tax under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”). to the minimum extent necessary so that such excise tax is not imposed. The Williams Employment Agreement also contains provisions intended to comply with Section 409A of the Code.

     

    The foregoing description of the Williams Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Williams Employment Agreement, which is included as Exhibit 10.1, to this Current Report on Form 8-K (the “Report”) and incorporated herein by reference.

     

    Employment Agreement with Blaine Browers

     

    On January 24, 2025, the Company and Mr. Blaine Browers entered into an Employment Agreement (the “Browers Employment Agreement”), which provides for Mr. Browers’ continued employment as Chief Financial Officer of the Company, for a term commencing effective as of the Commencement Date and terminating on the third anniversary of the Commencement Date, subject to earlier termination as provided therein. Mr. Browers is entitled to an annual base salary of $525,000, as more particularly provided in the Browers Employment Agreement.

     

    In addition to any other bonuses that the Board or the Compensation Committee of the Board may award to Mr. Browers in their sole discretion, Mr. Browers is entitled to receive annual performance bonuses, which may be based upon a variety of qualitative and quantitative factors, of up to 130% of Mr. Browers’ annual base salary. Mr. Browers will also be entitled, at the sole and absolute discretion of the Board or the Compensation Committee, to participate in incentive plans of the Company, including but not limited to the Company’s 2021 Incentive Plan or such other stock incentive plan as the Company may have in effect from time to time. Such participation and awards shall be based upon, among other things, Mr. Browers’ performance and the Company’s performance, all as determined by the Compensation Committee of the Board, of up to 130% of the Base Compensation, which will be payable 50% in the form of stock options and 50% in the form of a restricted stock award.

     

    The Browers Employment Agreement also contains confidentiality obligations as well as a non- competition covenant and non-interference (relating to the Company’s customers), non-solicitation (relating to the Company’s employees) and non-disparagement provisions effective during the term of his employment and for a period of two years after the termination of his employment with the Company.

     

     

     

     

    In the event that Mr. Browers’ employment is terminated as a result of his death or disability, Mr. Browers or his estate will, subject to the provisions of the Browers Employment Agreement, be generally entitled to receive his accrued base salary through the date of such termination and earned but unpaid annual incentive bonus prorated for the portion of the year in which such termination occurred and all granted but unvested stock options and all unvested restricted stock (and only if the price target as set forth therein has been achieved, including the restricted stock grant awarded pursuant to Section  3(e) of the Employment Agreement dated as of July 9, 2021, by and between the Company and Mr. Browers (the “2021 Browers Restricted Stock Award”) shall immediately vest. In the event that Mr. Browers’ employment is terminated by the Company for “cause” (as defined in the Browers Employment Agreement), Mr. Browers will, subject to the provisions of the Browers Employment Agreement, be entitled to receive his accrued base salary through the date of such termination. In addition, all stock options, whether vested or unvested, and granted but unvested restricted stock will be null and void except that, in the event that Mr. Browers is terminated as a result of his failure to perform any reasonable directive of the Board, he will be entitled to retain any vested stock options, but subject to the terms of the respective plan and award agreement under which they were awarded.

     

    In the event that Mr. Browers’ employment is terminated by the Company without “cause” (as defined in the Browers Employment Agreement), Mr. Browers will, subject to the provisions of the Browers Employment Agreement, be entitled to receive an amount equal to one year of his base salary and reimbursement of any COBRA premium payments made by Mr. Browers during such one-year period, in each case payable in accordance with the Company’s normal payroll practices, provided that Mr. Browers executes a separation agreement and general release agreement that is satisfactory to the Company. In addition, all granted but unvested stock options and all unvested restricted stock (but not including the 2021 Browers Restricted Stock Award) will immediately vest.

     

    In the event that Mr. Browers’ employment is terminated by Mr. Browers other than as a result of a “change in control” (as defined in the Browers Employment Agreement), Mr. Browers will, subject to the provisions of the Browers Employment Agreement, generally be entitled to receive his accrued base salary and benefits through the date of such termination. In addition, all granted but unvested stock options and all unvested restricted stock will be null and void.

     

    In the event that Mr. Browers’ employment is terminated by either party within 30 days of a “change in control”, Mr. Browers will, subject to the provisions of the Browers Employment Agreement, generally be entitled to receive an amount equal to one year of his base salary payable in one lump sum within five business days after such termination and reimbursement of any COBRA premium payments made by Mr. Browers during such one-year period; provided that Mr. Browers executes a separation agreement and general release agreement that is satisfactory to the Company, and provided further that, in the event the Company or the acquiror requests Mr. Browers to provide consulting services described in the Browers Employment Agreement, then the lump sum payment of an amount equal to one year of his base salary shall be payable upon the expiration of such consulting period, and during such consulting period, Mr. Browers will be entitled to a consulting fee equal to what he would have otherwise been entitled to be paid under the Browers Employment Agreement during such period. In addition, all granted but unvested stock options and all unvested restricted stock (and only if the price target as set forth therein has been achieved, including the 2021 Browers Restricted Stock Award) shall immediately vest.

     

    In the event that Mr. Browers fails to comply with any of his obligations under the Browers Employment Agreement, including, without limitation, the non-competition covenant and the non-interference, non-solicitation and non-disparagement provisions, Mr. Browers will be required to repay the one year of base salary paid to him pursuant to the Company termination without cause or change in control provisions of the Browers Employment Agreement as of the date of such failure to comply and he will have no further rights in or to such payments payable to him pursuant to the Browers Employment Agreement. All payments and benefits provided under the Browers Employment Agreement shall be subject to Company’s compensation recovery policy and/or as required under applicable law, rule or regulation.

     

     

     

     

    The Browers Employment Agreement contains provisions designed to reduce (but not below zero) any payments otherwise required to be paid to Mr. Browers if the same would result in the imposition of an excise tax under Section 4999 of the Code to the minimum extent necessary so that such excise tax is not imposed. The Browers Employment Agreement also contains provisions intended to comply with Section 409A of the Code.

     

    The foregoing description of the Browers Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Browers Employment Agreement, which is included as Exhibit 10.2, to this Report and incorporated herein by reference.

     

    Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

     

    (e)       The disclosures set forth in Item 1.01 of this Report with respect to Mr. Williams and Mr. Browers, respectively, are incorporated herein by reference.

     

    Item 9.01   Financial Statements and Exhibits

     

    (d)       Exhibits. The following Exhibit is filed herewith as a part of this Report:

     

    Exhibit Description
       
    10.1 Employment Agreement, dated as of January 24, 2025, between Cadre Holdings, Inc.  and Brad Williams.
       
    10.2 Employment Agreement, dated as of January 24, 2025, between Cadre Holdings, Inc.  and Blaine Browers.
       
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated:  January 27, 2025

     

      CADRE HOLDINGS, INC.
       
      By: /s/ Blaine Browers
      Name: Blaine Browers
      Title: Chief Financial Officer

     

     

     

    Get the next $CDRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDRE

    DatePrice TargetRatingAnalyst
    8/13/2025$26.00Neutral → Underperform
    BofA Securities
    6/13/2025$38.00Buy → Neutral
    BofA Securities
    2/21/2024$32.00 → $38.00Buy
    ROTH MKM
    1/22/2024Outperform → Mkt Perform
    Raymond James
    9/6/2022$30.00Buy
    BofA Securities
    8/31/2022$32.00Buy
    Jefferies
    3/11/2022$25.00 → $27.00Outperform
    Raymond James
    11/29/2021$24.00Buy
    Lake Street
    More analyst ratings

    $CDRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kanders Warren B

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    3/24/26 4:15:13 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Williams Brad

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    3/20/26 4:18:22 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Browers Blaine

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    3/20/26 4:17:05 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cadre Holdings downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cadre Holdings from Neutral to Underperform and set a new price target of $26.00

    8/13/25 8:01:40 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cadre Holdings from Buy to Neutral and set a new price target of $38.00

    6/13/25 7:45:51 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    ROTH MKM reiterated coverage on Cadre Holdings with a new price target

    ROTH MKM reiterated coverage of Cadre Holdings with a rating of Buy and set a new price target of $38.00 from $32.00 previously

    2/21/24 9:51:23 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cadre Holdings to Acquire Assets of Tedder Industries, Including Alien Gear Holsters

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, today announced that it has agreed to acquire Alien Gear Holsters and certain assets from Tedder Industries, LLC, for $10.3 million through a court-supervised bankruptcy auction. Cadre President Brad Williams commented, "This transaction represents a compelling opportunity to acquire a recognized holster brand with an established direct-to-consumer presence. Alien Gear brings an experienced team with a customer-first mindset, and we are excited about the attr

    3/26/26 10:24:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Annual Net Sales of $610.3 Million, Gross Margin of 42.5% and Net Income of $44.1 Million Achieved Record Annual Adjusted EBITDA for Third Consecutive Year Expects Full Year 2026 Net Sales of $736 to $758 Million and Adjusted EBITDA of $136 to $141 Million, Reflecting Year-Over-Year Growth of 22% and 24%, Respectively, at Midpoints Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today its consolidated operating results for the quarter and year ended December 31, 2025. Net sales of $1

    3/10/26 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Subsidiary Is Awarded $86 Million in Contracts by General Dynamics European Land Systems

    Company will Provide Life-Saving Blast Attenuation Seats in Support of Military Vehicle Crew Survivability Programs Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company") announced today that its subsidiary Med-Eng, LLC has been awarded two contracts with values of $74.6 million and $11.8 million by General Dynamics European Land Systems (GDELS) to provide blast attenuation seats. Delivering best-in-class protection, the seats will be deployed in the upcoming production of Mowag EAGLE V 4x4 command and control vehicles, and the Mowag EAGLE V 6x6 medium protected ambulance military vehicles. Cadre President Brad Williams commented, "These contracts represent another major win for Ca

    3/10/26 7:43:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    SEC Filings

    View All

    SEC Form 144 filed by Cadre Holdings Inc.

    144 - Cadre Holdings, Inc. (0001860543) (Subject)

    3/20/26 6:03:52 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Cadre Holdings Inc.

    10-K - Cadre Holdings, Inc. (0001860543) (Filer)

    3/10/26 4:19:19 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cadre Holdings, Inc. (0001860543) (Filer)

    3/10/26 4:15:27 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Financials

    Live finance-specific insights

    View All

    Cadre Holdings Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Annual Net Sales of $610.3 Million, Gross Margin of 42.5% and Net Income of $44.1 Million Achieved Record Annual Adjusted EBITDA for Third Consecutive Year Expects Full Year 2026 Net Sales of $736 to $758 Million and Adjusted EBITDA of $136 to $141 Million, Reflecting Year-Over-Year Growth of 22% and 24%, Respectively, at Midpoints Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today its consolidated operating results for the quarter and year ended December 31, 2025. Net sales of $1

    3/10/26 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings to Announce Fourth Quarter and Full Year 2025 Earnings and 2026 Financial Guidance on March 10, 2026

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today that it plans to release financial results for the fourth quarter that ended on December 31, 2025, on Tuesday, March 10, 2026, after the close of market trading. The company has scheduled a conference call to discuss these results on Wednesday, March 11, 2026, at 10:00 a.m. ET. The conference call will feature remarks by Warren Kanders, CEO and Chairman of the Board; Brad Williams, President; and Blaine Browers, Chief Financial Officer. To par

    2/24/26 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Increases Dividend

    Declares Quarterly Dividend of $0.10 Per Share; ~5% Increase on Annualized Basis Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per share, or $0.40 per share on an annualized basis, on the Company's common stock. On an annualized basis, the newly declared cash dividend represents an increase of 2 cents, or approximately 5%, over the previous annualized dividend of $0.38 per share. Cadre's dividend payment will be m

    1/20/26 4:42:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cadre Holdings Inc.

    SC 13G/A - Cadre Holdings, Inc. (0001860543) (Subject)

    11/12/24 9:50:14 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Cadre Holdings Inc.

    SC 13G - Cadre Holdings, Inc. (0001860543) (Subject)

    2/14/24 7:58:49 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Cadre Holdings Inc. (Amendment)

    SC 13G/A - Cadre Holdings, Inc. (0001860543) (Subject)

    2/12/24 4:15:31 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Leadership Updates

    Live Leadership Updates

    View All

    Cadre Holdings Appoints Gianmaria Delzanno to its Board of Directors

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced the appointment of Gianmaria Delzanno to its board of directors, effective as of January 13, 2025. Current Director Nicholas Sokolow, who joined the board of Cadre's predecessor in July of 2012, will retire from the Company's board, effective as of January 31, 2025. Upon Mr. Sokolow's departure, Mr. Delzanno will replace Mr. Sokolow as the lead independent director and will also serve as Chairman of the Nominating and Corporate Governance Committee as

    1/13/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Appoints Deborah DeCotis to its Board of Directors

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety and survivability equipment for first responders, announced the appointment of Deborah DeCotis to its board of directors, effective immediately. With Ms. DeCotis' appointment, the Board will expand to five directors, four of whom are independent. Ms. DeCotis will also serve on the Company's Compensation Committee. Ms. DeCotis has over 45 years of financial, advisory and business operations experience with a successful track record of leadership across multiple global institutions and industries. She currently serves as Advisory Director at Morgan Stanley & Co., Inc.

    4/12/22 8:30:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    ElectraMeccanica Appoints Automotive Veteran, William Quigley III, to Board of Directors

    VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- ElectraMeccanica Vehicles Corp. (NASDAQ:SOLO) ("ElectraMeccanica" or the "Company"), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, today announced the appointment of William (Bill) Quigley III to its Board of Directors. Mr. Quigley is an accomplished leader with a proven track record in large enterprises specific to the automotive industry. With 30 plus years in the industry, Bill's career has included the following key roles: Executive Vice President and Chief Financial Officer at Dana Holding Corporation, an automotive, commercial vehicle and off-highway driveline, sealing an

    4/7/22 8:05:00 AM ET
    $CDRE
    $SOLO
    Industrial Specialties
    Health Care
    Auto Manufacturing
    Consumer Discretionary